Henk Lokhorst

Summary

Affiliation: University Medical Center Utrecht
Country: The Netherlands

Publications

  1. doi request reprint Ocular graft-versus-host disease after allogeneic stem cell transplantation
    Arnaud C Westeneng
    Department of Ophthalmology, University Medical Center Utrecht, Utrecht, The Netherlands
    Cornea 29:758-63. 2010
  2. doi request reprint Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
    Henk M Lokhorst
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 119:6219-25; quiz 6399. 2012
  3. doi request reprint Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
    Henk M Lokhorst
    Department of Hematology, University Medical Center, Utrecht, The Netherlands
    Haematologica 93:124-7. 2008
  4. doi request reprint A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
    Henk M Lokhorst
    University Medical Center, Utrecht, The Netherlands
    Blood 115:1113-20. 2010
  5. doi request reprint International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma
    Henk Lokhorst
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    J Clin Oncol 28:4521-30. 2010
  6. pmc The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study
    Suzanne van Dorp
    Department of Immunology, UMC Utrecht, Utrecht, The Netherlands
    Haematologica 96:1380-4. 2011
  7. doi request reprint Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
    Annemiek Broyl
    Department of Hematology, Erasmus Medical Center and University, Rotterdam, The Netherlands
    Blood 116:2543-53. 2010
  8. ncbi request reprint Selective in vitro expansion and efficient retroviral transduction of human CD34+ CD38- haematopoietic stem cells
    Yuk Yin Ng
    Departments of Hematology and Immunology, University Medical Center, Utrecht, The Netherlands
    Br J Haematol 117:226-37. 2002
  9. ncbi request reprint Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy
    Robbert Spaapen
    Authors Affiliations Departments of Clinical Chemistry and Haematology, Immunology, and Haematology, University Medical Center Utrecht, The Netherlands
    Clin Cancer Res 13:4009-15. 2007

Collaborators

Detail Information

Publications9

  1. doi request reprint Ocular graft-versus-host disease after allogeneic stem cell transplantation
    Arnaud C Westeneng
    Department of Ophthalmology, University Medical Center Utrecht, Utrecht, The Netherlands
    Cornea 29:758-63. 2010
    ..To determine the prevalence and manifestations of ocular graft-versus-host disease (GvHD) after allogeneic stem cell transplantation (allo-SCT)...
  2. doi request reprint Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
    Henk M Lokhorst
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 119:6219-25; quiz 6399. 2012
    ..These results do not support a general application of allo-SCT in all myeloma patients as part of first-line therapy...
  3. doi request reprint Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
    Henk M Lokhorst
    Department of Hematology, University Medical Center, Utrecht, The Netherlands
    Haematologica 93:124-7. 2008
    ..However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms...
  4. doi request reprint A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
    Henk M Lokhorst
    University Medical Center, Utrecht, The Netherlands
    Blood 115:1113-20. 2010
    ..77). Patients randomized to thalidomide had strongly reduced survival after relapse. This trial was registered on www.controlled-trials.com as ISRCTN06413384...
  5. doi request reprint International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma
    Henk Lokhorst
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    J Clin Oncol 28:4521-30. 2010
    ..To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group...
  6. pmc The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study
    Suzanne van Dorp
    Department of Immunology, UMC Utrecht, Utrecht, The Netherlands
    Haematologica 96:1380-4. 2011
    ..Imbalances in B-cell homeostasis could be used to identify patients a priori with a higher chance of response to rituximab treatment (Eudra-CT 2008-004125-42)...
  7. doi request reprint Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
    Annemiek Broyl
    Department of Hematology, Erasmus Medical Center and University, Rotterdam, The Netherlands
    Blood 116:2543-53. 2010
    ..To conclude, in addition to 7 clusters described in the UAMS classification, we identified 3 novel subsets of multiple myeloma that may represent unique diagnostic entities...
  8. ncbi request reprint Selective in vitro expansion and efficient retroviral transduction of human CD34+ CD38- haematopoietic stem cells
    Yuk Yin Ng
    Departments of Hematology and Immunology, University Medical Center, Utrecht, The Netherlands
    Br J Haematol 117:226-37. 2002
    ....
  9. ncbi request reprint Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy
    Robbert Spaapen
    Authors Affiliations Departments of Clinical Chemistry and Haematology, Immunology, and Haematology, University Medical Center Utrecht, The Netherlands
    Clin Cancer Res 13:4009-15. 2007
    ....